Biotech Values

[dewophile]

GSK
the market absolutely hates this deal for GSK down 8% as I type. It's no secret they plan to re-enter the oncology space and have a good chance to add a second product w their BCMA ADC. I have no position in GSK but I may look to start one. They do have a lot of debt but most of this deal can be paid for once they close the sale of their nutrition business